Lijun International Pharmaceutical (Holding) Co. Ltd.
Lijun International Pharmaceutical (Holding) Co., Limited (
segments:Business segments
- manufacturing and selling of intravenous infusion solution
- manufacturing and selling of antibioticsand others
The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005).
The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.
Subsidiaries
The Company’s subsidiaries include:
- New Orient Limited (New Orient) in Hong Kong
- Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province(acquired in June 2007)
- Xi’an Lijun Pharmaceutical Co., Limited (Xi’an Lijun), engaged in manufacturing pharmaceuticals in Shaanxi Province
- Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.
The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.
Facing more
medical reform in China
, the Group is positioned for continuous mergers and acquisitions to promote its growth.